Details
Stereochemistry | MIXED |
Molecular Formula | C24H33NO3.C2H2O4 |
Molecular Weight | 473.5586 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C(O)=O.CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C23
InChI
InChIKey=SSAJNPNVUYMUCI-UHFFFAOYSA-N
InChI=1S/C24H33NO3.C2H2O4/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20;3-1(4)2(5)6/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3;(H,3,4)(H,5,6)
Molecular Formula | C24H33NO3 |
Molecular Weight | 383.5237 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C2H2O4 |
Molecular Weight | 90.0349 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. The drug act as a selective antagonist of 5-HT2 receptors. Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftoling, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax. Praxilene belongs to a group of medicines known as ‘metabolic activators’. These are used to treat different types of blood circulation problems. Praxilene allows the body to make better use of the oxygen in your blood. Praxilene is used to treat the following symptoms: cramp-like pains; cramps in legs at night; severe pain in r legs when people are resting (rest pain); pale or blue fingers or toes which get worse when it is cold; numbness, tingling or burning feelings in the fingers or toes (Raynaud’s syndrome or acrocyanosis); open sores on the legs or feet (trophic ulcers); poor circulation caused by diabetes (diabetic arteriopathy).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095200 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1369714 |
0.06 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Praxilene Approved UseUnknown Launch Date1.45186554E12 |
PubMed
Title | Date | PubMed |
---|---|---|
[Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication]. | 2001 Apr |
|
Treatment alternatives for nocturnal leg cramps. | 2001 May 21 |
|
Effect of naftidrofuryl on intramuscular partial oxygen pressure (pO2) prior to, during and after physical load on the treadmill in apparently healthy subjects. | 2002 |
|
Naftidrofuryl exerts antiserotonergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells and isolated perfused rat kidneys. | 2002 Jan |
|
Vitamin A metabolism is altered in brown Norway and long-Evans rats infused with naftidrofuryl or erythromycin intravenously. | 2002 Jul |
|
Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. | 2002 Mar |
|
Nocturnal leg cramps in older people. | 2002 Oct |
|
Raynaud's phenomenon (primary). | 2003 Jun |
|
Naftidrofuryl-induced liver injury. | 2003 Jun |
|
Drug treatment of intermittent claudication. | 2004 |
|
Therapy of hearing disorders - conservative procedures. | 2005 |
|
Acral necrosis after inadequate excessive administration of bleomycin in a testicular cancer patient. | 2005 Jan |
|
[Inpatient infusion treatment for acute tinnitus with and without adjuvant psychotherapeutic intervention. A comparison of psychological effectiveness]. | 2006 Oct |
|
Naftidrofuryl for acute stroke. | 2007 Apr 18 |
|
Prognostic indicators of management of sudden sensorineural hearing loss in an Asian hospital. | 2007 Jan |
|
Management of peripheral arterial disease in the elderly: focus on cilostazol. | 2008 |
|
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. | 2009 Mar 10 |
|
Pharmacologic therapy for intermittent claudication. | 2009 May |
|
Silence of the limbs pharmacological symptomatic treatment of intermittent claudication. | 2010 May |
|
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
The recommended dose is one or two capsules (100 mg naftidrofuryl oxalate) three times a day, for a minimum of three months
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7863151
After culture in a rat serum enriched with naftidrofuryl at concentration of 20 uM, we observed a protective effect of this drug toward the disruption of axonal microtubules by vinka alkaloids
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:24 UTC 2023
by
admin
on
Fri Dec 15 15:01:24 UTC 2023
|
Record UNII |
5ADB8D9388
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID6045533
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
100000085688
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
7237
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
3200-06-4
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
m7707
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB03376MIG
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
CHEMBL1620794
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
5ADB8D9388
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
225233
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
18542
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
221-703-0
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY | |||
|
C87286
Created by
admin on Fri Dec 15 15:01:24 UTC 2023 , Edited by admin on Fri Dec 15 15:01:24 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |